Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic review

被引：5
作者：
Simons, Martijn [1 ,2 ]
Ramaekers, Bram [1 ]
Peeters, Andrea [1 ]
Mankor, Joanne [3 ]
Paats, Marthe [3 ]
Aerts, Joachim [3 ]
van Harten, Wim [4 ,5 ]
Retel, Valesca [4 ,5 ]
Joore, Manuela [1 ,2 ]
机构：
[1] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands
[2] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Univ Singel 40, NL-6229 ER Maastricht, Netherlands
[3] Erasmus MC, Dept Pulm Med, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[4] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Psychosocial Res & Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[5] Univ Twente, Dept Hlth Technol & Serv Res, Hallenweg 5, NL-7522 NH Enschede, Netherlands
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷
关键词：
Non-small cell lung cancer; Targeted therapies; Immunotherapies; Survival analysis; Overall survival; RANDOMIZED PHASE-III; OPEN-LABEL; 1ST-LINE TREATMENT; CARBOPLATIN-PACLITAXEL; COMPARING GEFITINIB; CHEMOTHERAPY; ERLOTINIB; DOCETAXEL; ADENOCARCINOMA; MULTICENTER;
D O I：
10.1016/j.critrevonc.2020.103035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Outcomes used for the effectiveness (median) and cost-effectiveness (mean) on overall survival (OS) are different and can vary from one another. Therefore, we compared median and mean OS gains of targeted therapies and immunotherapies for stage IIIB/IV Non-small cell lung cancer and explored underlying aspect. Eligible trials were searched in PubMed, survival curves were digitized, and parametric survival models fitted to model the mean OS. Twenty-seven trials were found for targeted therapies (n = 17) and immunotherapies (n = 10). Differences between median and mean OS gains in months ranged from - 2.8 to 6.8 and - 4.9 to 0.3 for two different subgroups of targeted therapies, and -2.4 to 11.4 for immunotherapies. The mean OS gain was substantially larger for most immunotherapy trials, due to relatively long survival. Median and mean OS gains did not differ for targeted therapies. Our findings imply a potential discrepancy between the estimates of effectiveness and cost-effectiveness of cancer treatments.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Identifying Subsequent Therapies in Patients with Advanced Non-Small Cell Lung Cancer and Factors Associated with Overall Survival
    Afanasjeva, Janna
    Hui, Rita L.
    Spence, Michele M.
    Chang, Jennifer
    Schottinger, Joanne E.
    Millares, Mirta
    Rashid, Nazia
    PHARMACOTHERAPY, 2016, 36 (10): : 1065 - 1074
  • [2] Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists
    Costantini, Adrien
    Katsikas, Theodoros
    Bostantzoglou, Clementine
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2020, 16 (01) : 5 - 10
  • [3] Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
    Koban, Maren U.
    Hartmann, Markus
    Amexis, Georgios
    Franco, Pedro
    Huggins, Laura
    Shah, Imran
    Karachaliou, Niki
    CLINICAL CANCER RESEARCH, 2024, 30 (21) : 4822 - 4833
  • [4] Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Moya-Horno, Irene
    Viteri, Santiago
    Karachaliou, Niki
    Rosell, Rafael
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [5] Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
    Le, Alexander D.
    Alzghari, Saeed K.
    Jean, Gary W.
    La-Beck, Ninh M.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 223 - 236
  • [6] Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients
    Gridelli, C.
    Maione, P.
    Rossi, A.
    Ferrara, C.
    Colantuoni, G.
    Del Gaizo, F.
    Nicolella, D.
    Guerriero, C.
    TARGETED ONCOLOGY, 2006, 1 (01) : 13 - 22
  • [7] Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients
    C. Gridelli
    P. Maione
    A. Rossi
    C. Ferrara
    G. Colantuoni
    F. Del Gaizo
    D. Nicolella
    C. Guerriero
    Targeted Oncology, 2006, 1 : 13 - 22
  • [8] Cryoablation for advanced non-small cell lung cancer: a protocol for a systematic review
    Duan, Hua
    Zheng, Shu-Yue
    Luo, Chufan
    Fang, Xueni
    Wang, Dan
    Pang, Haoyue
    Wang, Man
    Chen, Yu
    Zhou, Tian
    Li, Quanwang
    Hu, Kaiwen
    BMJ OPEN, 2020, 10 (09):
  • [9] Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
    Wang, Yimin
    Li, Chuling
    Wang, Zimu
    Wang, Zhaofeng
    Wu, Ranpu
    Wu, Ying
    Song, Yong
    Liu, Hongbing
    BMC MEDICINE, 2022, 20 (01)
  • [10] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Cheng, Minyu
    Shao, Yanfei
    Li, Li
    Jiang, Menglao
    Song, Zhouye
    BMC CANCER, 2024, 24 (01)
12345